DURECT (NASDAQ:DRRX) Releases Earnings Results, Beats Expectations By $0.06 EPS

Key Points

• DURECT (NASDAQ:DRRX) reported an earnings per share (EPS) of ($0.07), exceeding analysts' estimates by $0.06.
• The stock price of DURECT increased to $1.91 during trading, with market capitalization around $59.29 million.
• Analysts have recently downgraded DURECT’s rating, with Northland Capital Markets changing it from a "strong-buy" to a "hold" as of July 29th.

DURECT (NASDAQ:DRRX - Get Free Report) posted its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.06, Zacks reports. DURECT had a negative return on equity of 267.36% and a negative net margin of 91.54%.

DURECT Price Performance

DRRX stock traded up $0.04 during mid-day trading on Tuesday, reaching $1.91. The company had a trading volume of 327,525 shares, compared to its average volume of 453,560. The stock has a 50 day simple moving average of $0.86 and a two-hundred day simple moving average of $0.77. The company has a market capitalization of $59.29 million, a price-to-earnings ratio of -12.73 and a beta of 0.83. DURECT has a 52 week low of $0.48 and a 52 week high of $2.64.

Analysts Set New Price Targets

DRRX has been the subject of a number of research reports. Northland Capmk downgraded DURECT from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 29th. Wall Street Zen initiated coverage on DURECT in a report on Thursday, May 22nd. They set a "sell" rating for the company.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.